

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UBA INVESTMENTS LIMITED

開明投資有限公司*

(incorporated in Cayman Islands with limited liability)
(Stock code: 768)

**ANNOUNCEMENT MADE PURSUANT TO
RULES 13.51(2)(u) AND 13.51B(2) OF THE LISTING RULES**

This announcement is made by UBA Investments Limited (the “Company”) pursuant to Rules 13.51(2)(u) and 13.51B(2) of the Rules Governing the Listing of Securities (the “Listing Rules”) on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

The board of directors (the “Board”) of the Company has been recently informed by Dr. WONG Yun Kuen (“Dr. Wong”), the chairman of the Board and an executive director of the Company, that he was named as one of the respondents in a petition dated 18 December 2020 (the “Petition”) filed with the Court of First Instance of the High Court of Hong Kong by the Securities and Futures Commission of Hong Kong (the “SFC”) pursuant to section 214 of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) in the matter of Superb Summit International Group Limited, the shares of which were delisted from the Stock Exchange in June 2020 (the “Delisted Company”).

The SFC alleged in the Petition that, among other things, the directors of the Delisted Company (including Dr. Wong, who was an independent non-executive director from April 2007 to June 2010) had failed to discharge their duties with due and reasonable care, skill and diligence as the management of the Delisted Company.

The Board has been informed by Dr. Wong that he disagrees with the allegations of the SFC in the Petition, and intends to contest the Petition vigorously.

As the Petition does not involve the Company or any of its subsidiaries (the “Group”), the Board, except Dr. Wong, has assessed the impact of the allegations and the Petition that have been instituted against Dr. Wong and concluded that currently there is no impact on the Group and no impairment to Dr. Wong’s duties as the chairman of the Board and the executive director of the Company owing to the fact that the proceeding are still ongoing and not conclusive.

Further announcement(s) will be made by the Company as and when further developments should arise in accordance with the Listing Rules.

By order of the Board
UBA INVESTMENTS LIMITED
LEUNG Man Lai
Company Secretary

Hong Kong, 24 December 2020

** For identification purpose only*

As at the date of this announcement, the Board of the Company consists of Dr. WONG Yun Kuen as chairman and executive director and Mr. CHENG Wai Lun, Andrew as executive director; Mr. CHAN Chung Yee, Alan, Dr. FUNG Lewis Hung, Mr. TANG Hon Bui, Ronald and Mr. KWOK Ming Fai as independent non-executive directors.